The Effect of Phaleria macrocarpa Bioactive Fraction (Proliverenol) Supplementation on Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Irsan Hasan; Saut Horas Hatoguan Nababan; Raymond R. Tjandrawinata; Danang Agung Yunaidi; Liana W. Susanto

doi:10.56951/a4ba3z37

The Effect of Phaleria macrocarpa Bioactive Fraction (Proliverenol) Supplementation on Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Penulis

Irsan Hasan Division of Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Saut Horas Hatoguan Nababan Division of Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Raymond R. Tjandrawinata Dexa Laboratories of Biomolecular Sciences, Cikarang, West Java, Indonesia and Center for Pharmaceutical and Nutraceutical Research and Policy, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
Danang Agung Yunaidi PT Equilab International, Contract Research Organization, Jakarta, Indonesia
Liana W. Susanto Dexa Laboratories of Biomolecular Sciences, Cikarang, West Java, Indonesia

DOI:

https://doi.org/10.56951/a4ba3z37

Kata Kunci:

Mahkota dewa, NAFLD, penyakit hati, Phaleria macrocarpa, Proliverenol

Abstrak

Hati merupakan salah satu organ paling vital yang bertindak sebagai pusat metabolisme nutrisi dan ekskresi produk buangan. Penyakit hati berlemak non-alkohol (non-alcoholic fatty liver disease/NAFLD) adalah salah satu penyebab utama penyakit hati kronis. Manajemen NAFLD terus berkembang, dan dokter saat ini dihadapkan dengan berbagai pilihan alternatif, baik non-farmakologi maupun farmakoterapi, untuk menghindari penyakit hati yang lebih parah. Phaleria macrocarpa (Scheff.) Boerl., atau yang dikenal sebagai mahkota dewa di Indonesia, telah digunakan secara empiris untuk mengobati kanker, alergi, dan diabetes melitus. Proliverenol merupakan fraksi bioaktif eksklusif yang berasal dari buah kering Phaleria macrocarpa (Scheff.) Boerl. Proliverenol dilaporkan memiliki efek hepatoprotektif, antiinflamasi, antioksidan, dan antifibrotik. Studi ini menunjukkan bahwa fraksi bioaktif Proliverenol, pada dosis 1000 mg dua kali sehari selama setidaknya 4 minggu pengobatan, merupakan dosis yang efektif untuk meningkatkan fungsi hati dengan profil keamanan yang baik.

Unduhan

Baca Selengkapnya

Referensi

1. Adiwinata R, Kristanto A, Christianty F, Richard T, Edbert D. Tatalaksana Terkini Perlemakan Hati Non- Alkoholik. Jurnal Penyakit Dalam Indonesia| Vol. 2015;2(1).

2. Berlian G, Tandrasasmita O, Tjandrawinata R. Bioactive fraction Proliverenol posseses hepatoprotective activity via anti-inflamation, DNA repair and antiapoptosis activities, s.l.: Unpublished report. Dexa Laboratories of Biomolecular Sciences. 2013:1-10.

3. Sundari N, Soetikno V, Louisa M, Wardhani BW, Tjandrawinata RR. Protective effect of Phaleria macrocarpa water extract (Proliverenol) against carbon tetrachloride‐induced liver fibrosis in rats: role of TNF‐α and TGF‐β1. Journal of Toxicology. 2018;2018(1):2642714.

4. Wardhani BW, Sundari N, Tjandrawinata RR, Jusuf AA, Soetikno V, Louisa M. Antifibrotic activity of Phaleria macrocarpa extract in rat liver-fibrosis model: focus on oxidative stress markers, TGF-β1 and MMP-13. Open Access Maced J Med Sci. 2020;8(A):555-62.

5. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. Journal of clinical and translational hepatology. 2017;5(4):384.

6. Hajaghamohammadi AA, Ziaei A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Hepat Month. 2008;8(3):191-5.

7. WHO Discussion Paper. Draft recommendations for the prevention and management of obesity over the life course, including potential targets. 2021.

8. Loomis AK, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. The Journal of Clinical Endocrinology & Metabolism. 2016 Mar 1;101(3):945-52.

9. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99(10):1946-52.

10. Javed A, Mehboob K, Rashid A, Majid A, Khan S, Baig ZA. Oxidative stress and lipid peroxidation in NAFLD with and without type 2 diabetes mellitus. J Coll Physicians Surg Pak. 2023;33:1254-8.

11. Potoupni V, et al. Circulating tumor necrosis factor‐α levels in non‐alcoholic fatty liver disease: a systematic review and a metaanalysis. J Gastroenterol Hepatol. 2021;36(11):3002-14.

12. Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, Hahn M, Webb M, Shibolet O, Kariv R, Tirosh O. Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants. 2020;9(7):578.

13. Ma Q, Liao X, Shao C, Lin Y, Wu T, Sun Y, Feng ST, Ye J, Zhong B. Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC gastroenterology. 2021;21:1-8.

14. Hosseini SA, Alipour M, Sarvandian S, Haghighat N, Bazyar H, Aghakhani L. Assessment of the appropriate cut-off points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease. BMC Endocrine Disorders. 2024;24(1):79.